 Haemonetics posted another quarterly beat, with exceptionally strong results from the Plasma business as plasma-derived therapy companies look to rebuild inventories. Between a looming recession and growth in demand for plasma-derived therapies, Haemonetics should be looking at several years of healthy demand in its core consumables-driven Plasma business. 